Acta Pharma Reports ISSN 3041-5381 is a biannually peer-reviewed multi-disciplinary pharmaceutical publication to serve as a means for scientific information exchange in the international pharmaceutical forum. It accepts novel findings that contribute to advancement of scientific knowledge in pharmaceutical fields that not been published or under consideration for publication anywhere else for publication in JRPS as original research article and all aspects of pharmaceutical sciences consisting of medicinal chemistry, molecular modeling, drug design, pharmaceutics, bio-pharmacy, pharmaceutical nanotechnology, pharmacognosy, natural products, pharmaceutical biotechnology, pharmacology, toxicology and clinical pharmacy.
The journal is registered with the following abstracting partners:
American Society of Health System Pharmacists, Baidu Scholar, Previews, CNKI (China National Knowledge Infrastructure Ex Libris – Primo Central, Google Scholar, Hinari, Infotrieve, National Science Library, ProQuest, TDNet, Wanfang Data
Submit Proposal
Acta Pharma Reports [ISSN 3041-5381] runs special issues to create collections of papers on specific topics. The aim is to build a community of authors and readers to discuss the latest research and develop new ideas and research directions. Special Issues are led by Guest Editors who are experts in the subject and oversee the editorial process for papers. Papers published in a Special Issue will be collected together on a dedicated page of the journal website. For any inquiries related to a Special Issue, please contact the Editorial desk at editor@pharma.researchfloor.org or submission@pharma.researchfloor.org
Acta Pharma Reports
[ISSN: 3041-5381 (Online)]
Frequency 2 issues per year
Language-English
Subject: Pharmaceutical Sciences
Starting Year 2022
Format of publication –Online
Country of Publication-Belgium
Discover the Latest in Pharmaceutical Sciences with the Journal of Acta Pharma Reports. Explore Groundbreaking Research, Innovation, and Insights. Stay Ahead in Pharma’s Dynamic Landscape.
INTRODUCTION“The Emergency Use Authorisation (EUA)” framework was established in 2004 during “The Project Bioshield Act 2004”, in the “Federal Food, Drug and Cosmetic Act”, to ratify the use of specific
Though technology comprises various facets, one broad definition is technology as the use of computers, computer systems, and other forms of technology to manage, process, and disseminate information. Technology covers
Introduction Cancer remains a leading cause of morbidity and mortality worldwide, with projections indicating a substantial escalation in burden over the coming decades [1]. In 2023, approximately 18.5 million new
1. Introduction Diabetes mellitus is one of the leading and prominent metabolic disorder with a myriad of aetiologies that include chronic hyperglycaemia and abnormality in the carbohydrate metabolism by the
Introduction Antibiotics have revolutionised the treatment of infectious diseases and dramatically decreased morbidity and mortality globally, making them one of the most revolutionary discoveries in contemporary medicine [1]. Antibiotics have
1. Introduction The development of vaccines has changed the course of infectious illnesses and world health in significant ways, making them a landmark achievement in medical history [20]. Modern immunisation
Introduction Diagnostic cytology, focuses on the examination of individual cells to assess their structure, function, and intrinsic properties. The first application of cytology in skin disorders was introduced by Tzanck
Rheumatoid arthritis (RA) is a chronic, systemic autoimmune disorder that affects millions worldwide, significantly diminishing quality of life. Unlike osteoarthritis, which arises due to mechanical wear and tear, RA is
Introduction Migraine is a complex and disabling neurological disorder that extends far beyond a simple headache, affecting over a billion individuals globally. It is characterized by intense unilateral throbbing pain,
